Acute Coronary Syndrome (ACS) Clinical Trial
Official title:
A Randomized Controlled Trial on the Switch From Ticagrelor to Clopidogrel in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention--OPTImal Management of Antithrombotic Agents: OPTIMA-5
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI) in China. Patients on maintenance dosing (MD) of aspirin (100 mg/d) and ticagrelor (90 mg twice daily) will be divided into two groups switching from ongoing ticagrelor to clopidogrel 600 mg loading dose (LD)/ 75 mg MD according to their bleeding risk. Then each group will randomly switch at different times(24 hours/ 12 hours after the last MD of ticagrelor). Pharmacodynamic assessments are performed at baseline, and at 4h, 8h, 24h, 48h, 72h hours with platelet aggregation rate by Light Transmittance Aggregometry method (LTA). All patients are followed-up for 30 days.
The primary endpoint of the study was platelet inhibition measured by Light Transmittance Aggregometry method(LTA). Secondary clinical endpoints included a 30-day major adverse cardiovascular endpoint (MACE) defined as a composite of cardiovascular death, recurrent myocardial infarction, target vessel revascularisation or stroke and individual components of the MACE. Safety endpoints of 30-day TIMI major and minor bleed were also evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00385138 -
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
|
Phase 3 | |
| Completed |
NCT01944800 -
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
| Completed |
NCT02290080 -
Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
|
Phase 3 | |
| Completed |
NCT02286544 -
Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01405287 -
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
|
Phase 2 | |
| Completed |
NCT00767507 -
Maintenance of Platelet Inhibition With Cangrelor
|
Phase 2 | |
| Completed |
NCT03672097 -
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Completed |
NCT00399880 -
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
|
N/A | |
| Completed |
NCT02430493 -
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
|
N/A | |
| Completed |
NCT01994577 -
Optimum Troponin Cutoffs for ACS in the ED
|
||
| Completed |
NCT00313300 -
Safety Study of Apixaban in Recent Acute Coronary Syndrome
|
Phase 2 | |
| Completed |
NCT02244710 -
EndoTic - Endothelium and Ticagrelor
|
N/A | |
| Active, not recruiting |
NCT04090281 -
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
|
Phase 4 | |
| Active, not recruiting |
NCT03581578 -
VITROS Immunodiagnostic Products hs Troponin I
|
||
| Completed |
NCT02171065 -
PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
|
N/A | |
| Completed |
NCT00855257 -
Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome
|
Phase 3 | |
| Completed |
NCT02733341 -
The Effect of IV Cangrelor and Oral Ticagrelor Study
|
Phase 4 | |
| Completed |
NCT02184884 -
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
|
||
| Completed |
NCT00932100 -
A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
|
Phase 2 | |
| Recruiting |
NCT02018497 -
Essential Hypotension and Allostasis Registry
|